Trademark Attorney / Law Firm

Branfman Mayfield Bustarde Reichenthal LLP – Trademark Portfolio

Branfman Mayfield Bustarde Reichenthal LLP specializes in Class 5 (Pharmaceuticals) trademark filings before the United States Patent and Trademark Office (USPTO), with 2 of 2 total filings concentrated in this category. Filing activity spans from 2023 to 2025. Currently, 2 trademarks are registered.

2 Total Trademarks
Loading...
By Date
By Name
Filter by Class:

Practice Areas by Trademark Class

Branfman Mayfield Bustarde Reichenthal LLP's trademark practice covers 1 Nice Classification class, representing the range of industries and goods/services handled in their USPTO filings.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademark applications has Branfman Mayfield Bustarde Reichenthal LLP filed?

Branfman Mayfield Bustarde Reichenthal LLP has filed 2 trademark applications with the United States Patent and Trademark Office (USPTO). Of these, 2 registered.

What trademark classes does Branfman Mayfield Bustarde Reichenthal LLP specialize in?

Branfman Mayfield Bustarde Reichenthal LLP has filed trademarks across 1 Nice Classification class. The most common practice areas include Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

How long has Branfman Mayfield Bustarde Reichenthal LLP been filing trademarks?

Branfman Mayfield Bustarde Reichenthal LLP's trademark filing history with the USPTO spans from 2023 to 2025, covering 2 years of trademark practice. During this period, Branfman Mayfield Bustarde Reichenthal LLP has handled 2 trademark applications.

What is Branfman Mayfield Bustarde Reichenthal LLP's trademark registration success rate?

Branfman Mayfield Bustarde Reichenthal LLP has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.